In this study, we found that alisertib treatment not only induced B7-H3 expression in glioma cell but also improved the immune microenvironment in mouse models, potentially increasing the response of tumors to anti–B7-H3 immunotherapy (41). This evidence concerns the gene CD276 and glioma.